Statin use may lower risks of osteoporosis, fracture in stroke patients
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
Poststroke statin use correlated with a decreased overall risk of the primary outcome of osteoporosis, hip fractures and vertebral fracture (adjusted hazard ratio [aHR], 0.66; p<0.001). Subanalyses revealed a correlation between statin use and a lower risk of all individual outcomes, including osteoporosis (aHR, 0.68; p<0.001), hip fracture (aHR, 0.59; p<0.001) and vertebral fracture (aHR, 0.73; p=0.003).
There was a dose-effect relationship between the outcomes and statin use. The aHRs for developing the primary outcome were 0.96 for patients who used 1–90 cumulative defined daily doses of statins, 0.86 for 91–365 and 0.34 for >365. These dose-effect relationships persisted in subgroup analyses stratified by age, sex and stroke type and sensitivity analyses conducted without propensity score matching.
This population-based propensity score-matched cohort study examined the association between statin use and risks of osteoporosis and fracture in stroke patients using Taiwan’s National Health Insurance Research Database.
The authors identified patients newly diagnosed with a stroke between 2000 and 2012. A total of 5,254 patients were included after propensity-score matching. Cox proportional hazards regression models according to statin use status were generated to calculate HRs for poststroke osteoporosis, hip fracture and vertebral fracture.
“Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden,” the authors noted.